Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, is seeking legal advice and will make an announcement on its future amid a lack of funds to continue operating.
The company had its shares halted from trading on the NZX and ASX pending a statement.
In its notice to the ASX, it says the trading halt will end "when legal advice is received and an announcement is made about the future of the company due to the lack of funds for ongoing costs".
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Sky shares tank on subscriber warning
- Reserve Bank bans MediaWorks from media conferences after lockup leak
- Clinton shows she has bite in social media scrap with Trump
- Political week: The PM, foreign trusts, and the latest round in a 10 year debate
- RMA reforms running into heavy weather at select committee
Most listened to
- The Prime Minister’s tendency to behave like the Arthur Daley of NZ politics seems to invite this sort of attack
- Rabobank analyst Emma Higgins explains why America's big cheese eaters are good for NZ
- Chris Keall on Sky TV's perfect storm
- NZVCA executive director Colin McKinnon on the deals and divestments of 2015
- Lee Buchheit of US law firm Cleary Gottlieb explains why the crisis in the eurozone may not be over yet